ADAPTIVE BIOTECHNOLOGIES CORP
NASDAQ: ADPT (Adaptive Biotechnologies Corpor)
最近更新时间: 1小时之前18.69
-0.15 (-0.80%)
| 前收盘价格 | 18.84 |
| 收盘价格 | 18.84 |
| 成交量 | 1,050,161 |
| 平均成交量 (3个月) | 2,037,379 |
| 市值 | 2,853,312,256 |
| 价格/销量 (P/S) | 11.73 |
| 股市价格/股市净资产 (P/B) | 14.73 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业毛利率 | -74.84% |
| 营业利益率 (TTM) | -56.45% |
| 稀释每股收益 (EPS TTM) | -0.950 |
| 季度收入增长率 (YOY) | 25.20% |
| 总债务/股东权益 (D/E MRQ) | 115.90% |
| 流动比率 (MRQ) | 2.92 |
| 营业现金流 (OCF TTM) | -85.34 M |
| 杠杆自由现金流 (LFCF TTM) | -21.40 M |
| 资产报酬率 (ROA TTM) | -15.05% |
| 股东权益报酬率 (ROE TTM) | -61.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Adaptive Biotechnologies Corpor | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -4.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.90 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.35% |
| 机构持股比例 | 98.36% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Viking Global Investors Lp | 30 Sep 2025 | 29,993,708 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2025 | 3,650,646 |
| Amova Asset Management Americas, Inc. | 30 Sep 2025 | 3,650,646 |
| Ark Investment Management Llc | 30 Sep 2025 | 3,165,636 |
| Aristotle Atlantic Partners, Llc | 30 Sep 2025 | 3,126,719 |
| Driehaus Capital Management Llc | 30 Sep 2025 | 3,019,940 |
| Fred Alger Management, Llc | 30 Sep 2025 | 2,514,234 |
| Arrowstreet Capital, Limited Partnership | 30 Sep 2025 | 2,441,402 |
| Blue Water Life Science Advisors, Lp | 30 Sep 2025 | 2,145,145 |
| Macquarie Group Ltd | 30 Sep 2025 | 2,104,414 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 21.00 (BTIG, 12.36%) | 购买 |
| 中 | 20.00 (7.01%) | |
| 低 | 16.00 (Morgan Stanley, -14.39%) | 保留 |
| 平均值 | 19.40 (3.80%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 15.54 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 11 Nov 2025 | 16.00 (-14.39%) | 保留 | 14.53 |
| BTIG | 06 Nov 2025 | 21.00 (12.36%) | 购买 | 15.56 |
| 22 Oct 2025 | 19.00 (1.66%) | 购买 | 16.45 | |
| JP Morgan | 06 Nov 2025 | 20.00 (7.01%) | 购买 | 15.56 |
| 13 Oct 2025 | 17.00 (-9.04%) | 购买 | 15.50 | |
| Piper Sandler | 15 Oct 2025 | 20.00 (7.01%) | 购买 | 17.11 |
| Guggenheim | 30 Sep 2025 | 20.00 (7.01%) | 购买 | 14.96 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BENZENO SHARON | - | 17.47 | -606,402 | -10,602,893 |
| 累积净数量 | -606,402 | |||
| 累积净值 ($) | -10,602,893 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 17.47 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BENZENO SHARON | 职员 | 21 Nov 2025 | 自动卖出 (-) | 308,477 | 18.61 | 5,740,757 |
| BENZENO SHARON | 职员 | 21 Nov 2025 | 执行期权 | 308,477 | - | - |
| BENZENO SHARON | 职员 | 20 Nov 2025 | 自动卖出 (-) | 297,925 | 16.32 | 4,862,136 |
| BENZENO SHARON | 职员 | 20 Nov 2025 | 执行期权 | 201,993 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合